Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio Inc (GRI) is a clinical-stage biotechnology pioneer advancing novel NKT cell-targeted therapies for inflammatory and autoimmune disorders. This dedicated news hub provides investors and industry stakeholders with essential updates on therapeutic developments, financial disclosures, and strategic milestones.
Access timely reports on GRI-0621 (oral inhibitor for liver disease/dermatology) and GRI-0803 (autoimmune candidate), including clinical trial progress, regulatory filings, and peer-reviewed research. Our curated collection features press releases, earnings call transcripts, and partnership announcements directly from the company and verified sources.
Key coverage areas include phase trial results, intellectual property updates, executive leadership changes, and scientific conference presentations. Bookmark this page to monitor GRI Bio's progress in developing oral therapies that modulate immune responses through its proprietary NKT cell platform.
GRI Bio (NASDAQ: GRI) has announced definitive agreements for the exercise of existing warrants to purchase 762,236 shares of common stock at a reduced price of $1.00 per share, down from the original $14.30. In exchange, the company will issue new unregistered Series D-1 and D-2 warrants, each for up to 762,236 shares at $1.00 per share. The D-1 warrants have a 5-year term, while D-2 warrants have an 18-month term.
The offering, expected to close around October 22, 2024, is anticipated to generate gross proceeds of approximately $0.8 million. H.C. Wainwright & Co. is acting as the exclusive placement agent. GRI Bio plans to use the net proceeds for working capital and general corporate purposes. The new warrants are being offered in a private placement and have not been registered under the Securities Act.
GRI Bio (NASDAQ: GRI) presented positive preclinical data for its lead program GRI-0621 at the 22nd International Colloquium on Lung and Airway Fibrosis. The data demonstrated GRI-0621's ability to inhibit invariant Natural Killer T (iNKT) cell activity and reduce inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).
Key findings include:
- Increased expression of pro-fibrotic factors in IPF patients
- Increased IFN-γ producing NKT cells in IPF patients
- GRI-0621 treatment improved inflammatory, fibrotic, and pathological features in a bleomycin model of pulmonary fibrosis
GRI Bio is currently conducting a Phase 2a biomarker study of GRI-0621 in IPF patients, with interim data expected in Q4 2024 and topline results in Q1 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024). The event will take place from October 12-16, 2024, in Athens, Greece.
The company's abstract has been accepted for a poster presentation titled "Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis." Dr. Vipin Kumar Chaturvedi, GRI Bio's Chief Scientific Officer, will present the poster (Number PP 184) on Tuesday, October 15, 2024, from 3:30 PM to 5:00 PM EEST.
This presentation highlights GRI Bio's ongoing research in the field of lung fibrosis and demonstrates the company's commitment to advancing its innovative pipeline of NKT cell modulators for treating various diseases.
GRI Bio (NASDAQ: GRI) has received a 'Decision to Grant' notice from the Japan Patent Office for patent application No. 2023-000750, titled 'Prevention and Treatment of Inflammatory Conditions.' The patent covers compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in treating inflammatory, fibrotic, and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist.
Japan's pharmaceutical market, valued at approximately $106 billion in 2021, is the third largest worldwide. GRI Bio's lead program, GRI-0621, a small molecule RAR-βɣ dual agonist candidate, is currently in a Phase 2a study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Interim data is expected in Q4 2024 and topline data in Q1 2025.
GRI Bio (NASDAQ: GRI) has received authorization from the Australian MHRA and HREC to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in Australia. This expands the global reach of their clinical development and is expected to accelerate enrollment. The company remains on track to report interim data in Q4 2024 and topline data in Q1 2025.
The study will enroll approximately 36 subjects with IPF, randomized in a 2:1 ratio for GRI-0621 4.5mg or placebo, administered orally once daily for 12 weeks. The primary endpoint is safety and tolerability, with secondary endpoints including changes in serum biomarkers, pharmacokinetics, and pharmacodynamic activity. The study also includes a sub-study examining NKT cells in bronchoalveolar lavage fluid.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in a Virtual Investor CEO Connect segment. The event is scheduled for October 2, 2024, at 12:00 PM ET.
CEO Marc Hertz, PhD, will deliver a brief presentation followed by an interactive Q&A session. Investors can submit questions live during the event or in advance via email to GRI@jtcir.com. The presentation will be available as a live video webcast on the company's website, with a replay accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI) recently participated in a Virtual Investor KOL Connect segment, featuring Albert Agro, PhD, CMO of GRI Bio, and Dr. Helen Parfrey, a prominent expert in Idiopathic Pulmonary Fibrosis (IPF). The discussion focused on IPF, current patient experiences, and GRI Bio's lead program, GRI-0621. This small molecule RAR-βɣ dual agonist inhibits iNKT cell activity and has shown promise in improving fibrosis and inflammation markers in preliminary trials.
GRI Bio is advancing GRI-0621 through a Phase 2a biomarker study, with interim data expected in Q4 2024 and topline data in Q1 2025. The company aims to address the limitations of current IPF treatments, which have significant side effects and impact on overall survival. GRI-0621 represents a potential new therapeutic approach to halt disease progression in fibrotic diseases like IPF.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
CEO Marc Hertz, PhD, will deliver a presentation and engage in one-on-one meetings with qualified investors. A video webcast of the presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for registered attendees. The webcast will also be accessible on the company's website and archived for 90 days post-event.
GRI Bio (NASDAQ: GRI), a biotech company developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 2024 European Respiratory Congress (ERS) in Vienna, Austria. The company's abstract has been accepted for a poster presentation on September 9, 2024.
The presentation, titled 'Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis', will be delivered by Emily Calamita from Dr. Adam Byrne's laboratory at Imperial College London. This research aligns with GRI Bio's focus on NKT cell modulators and their potential applications in treating respiratory conditions.
The poster session, scheduled from 12:30 - 2:00 PM CEST, falls under the category of 'Novel Insights in the Pathogenesis of Pulmonary Fibrosis', highlighting the company's contributions to advancing understanding in this field.
GRI Bio (NASDAQ: GRI) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) on track with interim data expected in Q4 2024 and topline data in Q1 2025.
2. Net loss of $2.4 million for Q2 2024.
3. R&D expenses at $0.9 million, G&A expenses at $1.4 million.
4. Cash and equivalents of $6.4 million as of June 30, 2024.
5. Closed a public offering with gross proceeds of $4.0 million.
6. Cash runway expected into Q1 2025.
7. Expanded IP protection with Korean patent grant.
8. Presented positive preclinical data for GRI-0621 in IPF and GRI-0803 for systemic lupus erythematosus.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
